Cynthia L. Toze - Concepedia

Author

Cynthia L. Toze

University of British Columbia ORCID

Also Known As

C L Toze, C Toze, C. L. Toze, C. Toze, C.L Toze, C.L. Toze, CL Toze, Cindy L. Toze, Cindy Toze, Cynthia L Toze

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

University of British Columbia BC Cancer Agency Vancouver General Hospital Vancouver Hospital and Health Sciences Centre Princess Margaret Cancer Centre

About

Cynthia L. Toze is an author at University of British Columbia specializing in medicine, hematology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	35	1.7K
2	Health Sciences	12	14	517
3	Blood Transplantation	7	7	347
4	Public Health	1	1	35
5	Cell Biology	1	1	19

Cynthia L. Toze

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial Irwin Walker, Tony Panzarella, Stephen Couban, The Lancet Oncology Unrelated DonorsAnti-thymocyte GlobulinTransplantationMedicineHematology	2015	354
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy Carolyn Owen, Cynthia L. Toze, Anna Koochin, Blood	2008	240
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver Julye C. Lavoie, Joseph M. Connors, Gordon L. Phillips, Blood	2005	121
Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia Matthew Greenwood, Matthew D. Seftel, C G Richardson, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematology	2006	106
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group Diego Villa, Michael Crump, Tony Panzarella, Journal of Clinical Oncology	2013	99
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells Amina Kariminia, Shernan G. Holtan, Sabine Ivison, Blood	2016	91
Allogeneic haematopoietic stem‐cell transplantation for relapsed and refractory aggressive histology non‐Hodgkin lymphoma* Richard Doocey, Cynthia L. Toze, Joseph M. Connors, British Journal of Haematology Cell TherapyLymphoma RelapseTransplantation MedicineImmunologyPathology	2005	86
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels Donna L. Forrest, Shannon Trainor, Ryan R. Brinkman, Leukemia Research Hematological MalignancyChronic Myeloid LeukemiaMedicineHematologyPathology	2008	81
Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease Cynthia L. Toze, Alia Galal, Michael J. Barnett, Bone Marrow Transplantation Cell TherapyTransplantationChronic Lymphocytic LeukemiaImmunologyHematology	2005	79
Stem cell transplantation for myelofibrosis: a report from two Canadian centers Andrew Daly, K W Song, Thomas J. Nevill, Bone Marrow Transplantation TransplantationMarrow TransplantationBone Marrow FailureStem Cell MobilizationStem Cell Transplantation	2003	77

Page 1